PL426662A1 - Kompozycja do doszklistkowego podawania białka leczniczego - Google Patents

Kompozycja do doszklistkowego podawania białka leczniczego

Info

Publication number
PL426662A1
PL426662A1 PL42666218A PL42666218A PL426662A1 PL 426662 A1 PL426662 A1 PL 426662A1 PL 42666218 A PL42666218 A PL 42666218A PL 42666218 A PL42666218 A PL 42666218A PL 426662 A1 PL426662 A1 PL 426662A1
Authority
PL
Poland
Prior art keywords
composition
therapeutic protein
intravitreal administration
intravitreal
administration
Prior art date
Application number
PL42666218A
Other languages
English (en)
Other versions
PL239642B1 (pl
Inventor
Bogusław Machaliński
Maria Dąbkowska
Dorota Rogińska
Original Assignee
Pomorski Univ Medyczny W Szczecinie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pomorski Univ Medyczny W Szczecinie filed Critical Pomorski Univ Medyczny W Szczecinie
Priority to PL426662A priority Critical patent/PL239642B1/pl
Priority to EP19461505.0A priority patent/EP3610885B1/en
Publication of PL426662A1 publication Critical patent/PL426662A1/pl
Publication of PL239642B1 publication Critical patent/PL239642B1/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595Polyamides, e.g. nylon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02Polyamines
    • C08G73/028Polyamidoamines
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002Dendritic macromolecules
    • C08G83/003Dendrimers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Polymers & Plastics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL426662A 2018-08-16 2018-08-16 Kompozycja do doszklistkowego podawania białka leczniczego PL239642B1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL426662A PL239642B1 (pl) 2018-08-16 2018-08-16 Kompozycja do doszklistkowego podawania białka leczniczego
EP19461505.0A EP3610885B1 (en) 2018-08-16 2019-01-22 Composition for the intravitreal administration of therapeutic protein

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL426662A PL239642B1 (pl) 2018-08-16 2018-08-16 Kompozycja do doszklistkowego podawania białka leczniczego

Publications (2)

Publication Number Publication Date
PL426662A1 true PL426662A1 (pl) 2020-08-24
PL239642B1 PL239642B1 (pl) 2021-12-20

Family

ID=65817953

Family Applications (1)

Application Number Title Priority Date Filing Date
PL426662A PL239642B1 (pl) 2018-08-16 2018-08-16 Kompozycja do doszklistkowego podawania białka leczniczego

Country Status (2)

Country Link
EP (1) EP3610885B1 (pl)
PL (1) PL239642B1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL248905B1 (pl) * 2023-10-10 2026-02-09 Pomorski Univ Medyczny W Szczecinie Kompozycja farmaceutyczna do doszklistkowego podawania zawierająca co najmniej jedną substancję aktywną oraz nośnik, kompleks elektrostatyczny zawierający co najmniej jedną substancję aktywną oraz nośnik oraz jego zastosowanie

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4631337A (en) 1983-01-07 1986-12-23 The Dow Chemical Company Hydrolytically-stable dense star polyamine
US4737550A (en) 1983-01-07 1988-04-12 The Dow Chemical Company Bridged dense star polymers
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4871779A (en) 1985-12-23 1989-10-03 The Dow Chemical Company Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities
US4694064A (en) 1986-02-28 1987-09-15 The Dow Chemical Company Rod-shaped dendrimer
US4713975A (en) 1986-05-30 1987-12-22 The Dow Chemical Company Dense star polymers for calibrating/characterizing sub-micron apertures
US4857599A (en) 1988-02-08 1989-08-15 The Dow Chemical Company Modified dense star polymers
HUE055815T2 (hu) * 2007-10-05 2021-12-28 Univ Wayne State Vegyületek nyújtott felszabadítására alkalmas dendrimerek
CN101980668A (zh) * 2008-02-07 2011-02-23 赛拉基因公司 通过玻璃体内施用编码治疗用蛋白质的表达载体救援光感器
US8302052B2 (en) 2009-06-23 2012-10-30 Cadence Design Systems, Inc. Methods, systems, and computer program product for implementing hotspot detection, repair, and optimization of an electronic circuit design
JP6302091B2 (ja) * 2014-04-30 2018-03-28 ザ・ジョンズ・ホプキンス・ユニバーシティー デンドリマー組成物および眼の疾患の処置におけるその使用
CA3082121C (en) * 2017-11-10 2023-01-24 The Johns Hopkins University Dendrimer delivery system and methods of use thereof

Also Published As

Publication number Publication date
EP3610885B1 (en) 2022-07-06
EP3610885A1 (en) 2020-02-19
PL239642B1 (pl) 2021-12-20

Similar Documents

Publication Publication Date Title
IL276464A (en) Methods and preparations for administering therapeutic protein
GB2592822B (en) Therapeutic compositions
ZA202004025B (en) Novel compounds and pharmaceutical compositions thereof for the treatment of diseases
IL275639A (en) Formulation for RNA administration
IL279397A (en) New compounds and their pharmaceutical preparations for the treatment of diseases
IL276888A (en) Pharmaceutical compositions containing timolol
ZA202006264B (en) Stable formulations of therapeutic antibody
IL271777A (en) Preparations for intravenous administration of medical substances
IL288550A (en) Pharmaceutical compositions for fcrn inhibitors for subcutaneous administration
IL273451A (en) Pharmaceutical preparations for administration of peptides
SG11202108627SA (en) Therapeutic antibody formulation
IL279622A (en) Pharmaceutical formulations of masked antibodies
IL290039A (en) Platelet assisted delivery of therapeutic compounds
IL289338A (en) Therapeutic interactions of leucomethylthionine
IL279707A (en) A pharmaceutical preparation that includes a polypeptide
PL426662A1 (pl) Kompozycja do doszklistkowego podawania białka leczniczego
EP3897669A4 (en) METHODS AND COMPOSITIONS RELATING TO THERAPEUTIC PEPTIDES FOR CANCER THERAPY
SI3731817T1 (sl) Farmacevtski sestavek farmacevtsko sprejemljive adicijske soli lenalidomida s kislino
KR102388028B9 (ko) 폴리펩타이드 전달용 조성물
GB201812861D0 (en) Methods of administering therapy
HK40042312A (en) Methods and compositions for therapeutic protein delivery
HK40055503A (en) Methods and compositions related to therapeutic peptides for cancer therapy
GB201909868D0 (en) Therapeutic compositions
HK40016365A (en) Formulations for enteric delivery of therapeutic agents
GB201814764D0 (en) Pharmaceutical compositions for the treatment of proteinopathies